RANI Therapeutics
RANI · Nasdaq · United States
Share price · RANI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RANI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+15.9%
Nothing announced by RANI that day or the session before.
- 22 Jul 2026+29.8%
Nothing announced by RANI that day or the session before.
- 7 Jul 2026-10.6%
Nothing announced by RANI that day or the session before.
- 26 May 2026-12.1%
- 20 May 2026+23.3%
Nothing announced by RANI that day or the session before.
- 11 May 2026+10.8%
Nothing announced by RANI that day or the session before.
- 15 Apr 2026+14.7%
Nothing announced by RANI that day or the session before.
- 1 Apr 2026+9.5%
Nothing announced by RANI that day or the session before.
- 27 Mar 2026-24.9%
- 18 Mar 2026-9.2%
Nothing announced by RANI that day or the session before.
Share of unusual movement by asset
For each asset, the share of RANI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 75% |
| Sessions with no dated event | — | 25% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | GLP-1/GLP-2 receptor (dual) | Indication not yet linked |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.7M | $6.0M | $3.8M | $7.7M-$7.8M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.7M | $5.0M | $5.1M | $7.4M-$9.0M operating cash flow | report ↗ |
| 2026-Q1 | $1.7M | $5.2M | $9.8M | $7.0M-$6.5M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $3.2M | $4.6M | $5.4M-$5.1M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $5.5M | $11M | $6.7M-$5.8M operating cash flow | report ↗ |
| 2025-Q1 | $0.2M | $6.6M | $11M | $7.3M-$8.2M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $6.2M | $4.8M | $6.8M-$8.4M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $6.1M | $5.0M | $6.8M-$9.0M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $7.6M | $7.4M | $7.5M-$9.4M operating cash flow | report ↗ |
| 2023-Q3 | — | $11M | $5.5M | $9.2M-$14M operating cash flow | report ↗ |
| 2023-Q2 | — | $11M | $8.1M | $9.3M-$12M operating cash flow | report ↗ |
| 2023-Q1 | — | $9.7M | $19M | $8.4M-$12M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $9.1M | $28M | $8.0M-$12M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $9.5M | $97M | $7.6M-$10M operating cash flow | report ↗ |
| 2022-Q1 | — | $7.6M | $108M | $6.2M-$9.4M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $12M | $130M | $3.1M-$11M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.6M | $20M | $19M | $7.4M-$19M operating cash flow | report ↗ |
For FY2025, RANI Therapeutics reported revenue of $1.63M, up 58.3% YoY, with R&D spend of $20.2M, down 24.3% YoY. Cash and equivalents were $18.82M, and the company reported a net loss of $29.67M and quarterly net burn of $29.67M.
Operationally, RANI announced an up-to-$1.085B collaboration with Chugai, completed a $60.3M oversubscribed private placement, and repaid all outstanding debt. It reported preclinical data supporting oral delivery of semaglutide via RaniPill and bioequivalence of RT-114, and initiated a Phase 1 study of RT-114 for obesity in collaboration with ProGen. Management expects existing cash, including an expected Chugai milestone payment, to fund operations into the fourth quarter of 2027 and anticipates higher R&D expenses in future periods.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $1.0M | $27M | $4.3M | $7.5M-$36M operating cash flow | report ↗ |
| 2023-FY | $0 | $40M | $6.4M | $8.5M-$51M operating cash flow | report ↗ |
| 2022-FY | $0 | $37M | $28M+ $99M short-term inv. | $7.7M-$47M operating cash flow | report ↗ |
| 2021-FY | $2.7M | $26M | $118M | $2.1M-$32M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($50K), 1 sale ($301). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-27 | Javadi Alireza · Chief Technical Officer | Tax withholding | 309 | $0.76 | $235 | Form 4 |
| 2026-09-27 | Imran Talat · director, Chief Executive Officer | Tax withholding | 7,928 | $0.76 | $6K | Form 4 |
| 2026-08-03 | Gilson Michelle · director | Award / grant (derivative) | 247,200 | — | — | Form 4 |
| 2026-07-21 | IMRAN MIR A · director, 10% owner | Open-market purchase | 36,000 | $0.69 | $25K | Form 4 |
| 2026-07-17 | Maestas Nicholas · Chief Financial Officer | Award / grant (derivative) | 2,000,000 | — | — | Form 4 |
| 2026-07-17 | Imran Talat · director, Chief Executive Officer | Open-market purchase | 35,000 | $0.72 | $25K | Form 4 |
| 2026-06-27 | Javadi Alireza · Chief Technical Officer | Tax withholding | 309 | $0.74 | $229 | Form 4 |
| 2026-06-27 | Imran Talat · director, Chief Executive Officer | Tax withholding | 7,927 | $0.74 | $6K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 73 reporting institutions held 42.7M shares ($31.2M, 34.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 8,500,000 | $6.2M |
| 2 | SAMSARA BIOCAPITAL, LLC | 8,500,000 | $6.2M |
| 3 | AWM Investment Company, Inc. | 6,500,000 | $4.8M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4,622,567 | $3.4M |
| 5 | SymBiosis Capital Partners, LLC | 3,667,585 | $2.7M |
| 6 | Longaeva Partners L.P. | 2,329,459 | $1.7M |
| 7 | Siren, L.L.C. | 2,000,000 | $1.5M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 903,298 | $664K |
| 9 | BlackRock, Inc. | 556,889 | $409K |
| 10 | Nan Fung Group Holdings Ltd | 493,584 | $363K |
| 11 | 683 Capital Management, LLC | 487,168 | $358K |
| 12 | VANGUARD FIDUCIARY TRUST CO | 455,050 | $334K |
| 13 | MILLENNIUM MANAGEMENT LLC | 405,669 | $298K |
| 14 | STATE STREET CORP | 373,142 | $274K |
| 15 | UNITED SERVICES AUTOMOBILE ASSOCIATION | 302,743 | $222K |